Axsome Therapeutics (AXSM) Announces Settlement Agreement Resolving AUVELITY Patent Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Axsome Therapeutics (AXSM) PT Raised to $190 at TD Cowen, Top Pick
February 11, 2025 5:25 AM ESTTD Cowen analyst Joseph Thome raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $190.00 (from $155.00) while maintaining a Buy rating.
The analyst comments "Axsome announced it has resolved Teva patent litigation related to Auvelity, which will allow entry of a generic... More
Axsome Therapeutics (AXSM) PT Raised to $167 at BofA Securities
February 10, 2025 10:40 AM ESTBofA Securities analyst Jason Gerberry raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $167.00 (from $143.00) while maintaining a Buy rating.
The analyst comments "This morning, Axsome announced a patent settlement pertaining to Auvelity key terms include a license for sole generic challenger (TEVA) to come to market in the 2038-39 time frame. Auvelity is an antidepressant that we... More
